Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

Rhea-AI Summary

Invivyd announced its upcoming presentations at the 2024 ASCO Annual Meeting and the 2024 ATC. The presentations will cover preliminary subset analyses from the Phase 3 CANOPY trial of VYD222 (pemivibart), a monoclonal antibody aimed at preventing COVID-19.

At ASCO (May 31 – June 4, Chicago, IL), the focus will be on participants with significant immune compromise due to solid tumor or hematologic malignancies (Abstract# 2532). The poster presentation is scheduled for June 1 from 9 AM – 12 PM CDT.

At ATC (June 1 – June 5, Philadelphia, PA), the preliminary results for solid organ transplant patients will be discussed (Abstract #A018). The poster presentation is set for June 1 from 5:30 PM – 7 PM EST.

Posters will be available on the Invivyd website after the meetings.

Positive

• Invivyd to present at two major conferences (ASCO and ATC) in 2024, increasing visibility.
• Focus on the Phase 3 CANOPY trial of VYD222, showing progress in clinical development.
• Targeted analyses on specific high-risk groups (immune-compromised and transplant patients) highlight commitment to vulnerable populations.
• Scheduled presentations at recognized conferences can generate investor interest and market confidence.

Negative

• Data being presented are only subset analyses, which may not reflect the overall trial outcomes.
• No definitive results or conclusions from the Phase 3 CANOPY trial are included, keeping uncertainty high.
• Potential delays in obtaining full results and regulatory approvals could prolong market entry.
• financial data or projections provided, offering little insight into potential financial impacts.

WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present preliminary, subset analyses from the CANOPY Phase 3 clinical trial of VYD222 (pemivibart) for pre-exposure prophylaxis of COVID-19 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and at the 2024 American Transplant Congress (ATC).

The details for each meeting are as follows:

2024 ASCO Annual Meeting (May 31 – June 4, Chicago, IL)

• Abstract# 2532: A phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19 (CANOPY): Subset analysis of participants with significant immune compromise in the setting of solid tumor or hematologic malignancies.
• Poster Details: Board #11, Hall A; Saturday, June 1 from 9:00 AM – 12:00 PM CDT

2024 ATC (June 1 – June 5, Philadelphia, PA)

• Abstract #A018: Preliminary results for solid organ transplant patients enrolled in CANOPY, a phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19.
• Poster Details: Poster Hall, Exhibit Hall A‚ Level 2; Saturday, June 1 from 5:30 PM – 7:00 PM EST

Copies of the posters will be available on the Invivyd website under the ‘Scientific Publications’ section after the posters are presented at the meetings.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-0160
investors@invivyd.com

FAQ

What is Invivyd presenting at the 2024 ASCO Annual Meeting?

Invivyd will present subset analyses from the CANOPY Phase 3 trial of VYD222 focused on participants with significant immune compromise due to solid tumor or hematologic malignancies.

When will Invivyd present at the 2024 ATC?

Invivyd's presentation at the 2024 ATC will take place on June 1 from 5:30 PM – 7:00 PM EST.

What is VYD222?

VYD222, also known as pemivibart, is an IgG1 monoclonal antibody being investigated for the prevention of COVID-19.

What is the focus of Invivyd's research presented at ATC?

At the 2024 ATC, Invivyd will present preliminary results for solid organ transplant patients from the CANOPY Phase 3 study of VYD222.

Where can I find the posters presented by Invivyd at the ASCO and ATC meetings?

The posters will be available on the Invivyd website under the ‘Scientific Publications’ section after the meetings.